iPLA 2␤; iPLA2␥; cytoprotection MEMBERS OF the phospholipase A 2 (PLA 2 ) family of enzymes hydrolyze fatty acids from the sn-2 position of phospholipids, generating free fatty acids and lysophospholipids (34, 43) . Both products of this reaction have signaling properties. Moreover, arachidonic acid (AA) may be further metabolized by cyclooxygenase (COX) and lipoxygenase enzymes to bioactive eicosanoids. The PLA 2 s may be subdivided into three categories, including secretory PLA 2 s (sPLA 2 , groups I, II, III, V, VII-XIV), calcium-dependent PLA 2 s, e.g., cytosolic PLA 2 ␣ (cPLA 2 , group IV), and the most recently discovered calciumindependent PLA 2 s (iPLA 2 s, group VI) (34, 43) . cPLA 2 plays an important role in complement-mediated glomerular epithelial cell (GEC) injury in the passive Heymann nephritis (PHN) model of membranous nephropathy (19) . GEC, otherwise known as podocytes, are an important component of the glomerular permselective barrier (33, 38, 42) . In PHN and human membranous nephropathy, deposition of antibodies in the subepithelial region of the glomerulus leads to activation of complement and assembly of the C5b-9 membrane attack complex in GEC plasma membranes, leading to GEC injury and proteinuria. Studies in cultured GEC and in PHN indicate that C5b-9 induces sublethal GEC injury, which is associated with activation of protein kinases and phospholipases (including cPLA 2 ), upregulation of COX-2, production of reactive oxygen species, induction of endoplasmic reticulum (ER) stress response, and other effects. These pathways ultimately contribute to changes in GEC lipid composition and function, reorganization of the actin cytoskeleton, and displacement of filtration slit diaphragm proteins (19) .
Previous studies have demonstrated that assembly of C5b-9 in cultured GEC is linked to the activation of cPLA 2 and that glomeruli of rats with PHN demonstrate increased cPLA 2 activity compared with control glomeruli (23) . Activation of cPLA 2 leads to various cellular effects. First, in GEC, activation of cPLA 2 perturbs the membrane of the ER and contributes to induction of ER stress. Preconditioning of rats with compounds that induce ER stress can limit proteinuria in PHN (22) . Second, activation of cPLA 2 may contribute directly to the exacerbation of C5b-9-induced GEC injury (18, 23, 37) . Finally, the AA mobilized by cPLA 2 is metabolized by COX enzymes (44) to bioactive eicosanoids. Glomeruli from rats with PHN show increased COX-1 and COX-2 protein expression and enhanced production of prostaglandin (PG) E 2 and thromboxane A 2 . Blockade of COX enzymes reduces urinary protein excretion in PHN and in human membranous nephropathy (45, 46) .
The purpose of the present study was to determine whether complement could stimulate the activity of iPLA 2 . Among the various members of the iPLA 2 family, we focused on two isoenzyme subfamilies, so-called iPLA 2 -VIA-1 and -2 (iPLA 2 ␤ short and iPLA 2 ␤ long) and iPLA 2 -VIB (iPLA 2 ␥), each with unique structural features, especially in the NH 2 terminus (29, 31, 43) . Both iPLA 2 ␤ short and iPLA 2 ␤ long are functional enzymes, which differ by a 54-amino acid proline-rich insertion sequence (13) . Knockout mice lacking iPLA 2 ␤ show only impaired sperm motility (7) , while transgenic mice overexpressing the same isoform are prone to ventricular tachyarrhythmias (30) . iPLA 2 ␥ is a membrane-bound enzyme, with competing peroxisomal (COOH terminal) and mitochondrial (NH 2 terminal) localization signals (31) . iPLA2␥ also localizes in the ER (17) . iPLA 2 ␥ gene transcription and translation are complex (31) . iPLA 2 ␥ has multiple promoter sites, as well as a transcriptional repressor site in the 5Ј-untranslated region. The full-length 2.4-kb transcript contains 13 exons and includes four AUG translation initiation codons generating as many as 10 splice variants, which appear as 88-, 77-, 74-, and 63-kDa immunoreactive proteins on SDS-PAGE and immunoblotting (47) . iPLA 2 enzymes are active in basal phospholipid turnover, phospholipid accumulation during the G1/M phase of mitosis, and are involved at various levels of apoptotic cascades (2, 5) . iPLA2␥ was shown to be cytoprotective against oxidant insults in renal cells, presumably by removing oxidized phospholipids (17) . In contrast, inhibition of rabbit renal proximal tubule cell microsomal iPLA 2 ␥ during cisplatin-induced apoptosis reduced annexin V staining, chromatin condensation, and caspase-3 activation, indicating that iPLA 2 ␥ inhibition was cytoprotective (16) . Mitochondrial iPLA 2 ␥ has also been shown to actively participate in the permeability pore transition of the mitochondria and the release of the proapoptotic cytochrome c (25) . A recent study showed that iPLA 2 ␥ knockout mice display multiple bioenergetic dysfunctional phenotypes (32) . In addition, several potential pathophysiological roles have been described for the iPLA 2 s, including AA release for eicosanoid production, tumorigenesis, cell injury, apoptosis, chemotaxis, and others (2, 5, 35) .
In the present study, we have used cultured GEC to demonstrate that C5b-9 can stimulate an iPLA 2 14 C]arachidonyl-phosphatidylcholine (PC; 53 mCi/mmol), were purchased from PerkinElmer Life and Products (Boston, MA). Mouse iPLA 2␤ long and iPLA2␤ short cDNAs subcloned into pcDNA 3.1 were kindly provided by Dr. Suzanne Jackowski (University of Tennessee Health Centre, Memphis, TN), while human iPLA 2␥ cDNA in pcDNA 1.1 was provided by Drs. Richard Gross and David Mancuso (Washington University School of Medicine, St. Louis, MO). iPLA 2␥ antibody was kindly provided by Dr. Makoto Murakami (Showa University, Tokyo, Japan). Unless otherwise specified, all other chemicals and biochemical reagents were purchased from Sigma-Aldrich Canada (Mississauga, ON).
Cell culture, radiolabeling, and transfection. Rat GEC culture and characterization have been described previously (14, 40) . According to established criteria, the cells demonstrated cytotoxic susceptibility to low doses of aminonucleoside of puromycin, the presence of junctional complexes by electron microscopy, and expression of a variety of GEC antigens. GEC were maintained in K1 medium. COS cells and Chinese hamster ovary (CHO) cells were cultured in DMEM-10% fetal calf serum.
Phospholipids were radiolabeled to isotopic equilibrium by incubating cells with [ 3 H]AA (0.125 Ci/ml K1 medium) for 72 h (20) . At the end of incubations, supernatants and cells were collected, lipids were extracted with chloroform:methanol (1:1.2) and 0.2% formic acid, followed by chloroform, and were then dried under nitrogen. After reconstitution in chloroform:methanol (2:1) and addition of "cold" AA and 1,2-diacylglycerol (DAG) standards, the free AA and DAG were separated from other lipids by thin-layer chromatography in hexane:diethyl ether:acetic acid (80:20:2). Relevant bands were scraped, and radioactivity was quantified in a beta liquid scintillation counter (18, 37) . It should be noted that when using this method, we cannot exclude some oxidation of [ 3 H]AA. For expression of iPLA 2 enzymes, plasmids containing iPLA2␤ short or iPLA 2␥ cDNAs were transfected in GEC using the Lipofectamine 2000 reagent. Following selection by neomycin and expansion, all subclones were tested for overexpression of the enzyme by immunoblotting. Confirmation of enhanced enzyme activity was determined using an in vitro PLA 2 assay (described below). Characterization of GEC that overexpress cPLA 2 was published previously (18, 37) .
Incubation of GEC with complement. GEC were incubated with rabbit anti-GEC antiserum (5% vol/vol) in modified Krebs-Henseleit buffer containing (in mM) 145 NaCl, 5 KCl, 0.5 MgSO4, 1 Na2HPO4, 0.5 mmol/l CaCl2, 5 glucose, and 20 HEPES, pH 7.4, for 30 min at 22°C. The cells were then incubated at 37°C with normal human serum (NS; with full complement activity) or heat-inactivated serum (HIS; incubated at 56°C for 30 min to inactivate complement) as indicated. In experiments designed to measure Ca 2ϩ -independent [ 3 H]AA release, antibody-sensitized GEC were incubated with C8-deficient human serum (C8DS) in buffer containing 0.5 mM Ca 2ϩ for 40 min. Then, GEC were washed and incubated with or without purified C8 (2.0 g/ml) and C9 (1.5 g/ml) for 40 min in buffer containing 1 mM EGTA (18, 37) .
Preparation of cell extracts and in vitro assay of PLA2 activity. Cells were collected in homogenization buffer containing 50 mM HEPES, 0.25 M sucrose, 1 mM EDTA, 1 mM EGTA, 20 M leupeptin, 20 M pepstatin, and 0.1 mM PMSF, pH 7.4 (18, 37) . Following centrifugation for 3 min at 1,500 g, the pellet was homogenized with 25 strokes in a Wheaton homogenizer, centrifuged for 5 min at 2,500 g, and the supernatant was collected. The remaining pellet was again homogenized and centrifuged for 5 min with the supernatant being pooled with that collected earlier. The supernatant was centrifuged at 15,000 g for 20 min to remove any remaining insoluble membrane fractions.
To assay PLA2 activity (18, 37) , exogenous 2-[ 14 C]arachidonyl-PE or PC (substrate; 3.5 M) was dried under a stream of nitrogen and reconstituted in 2 l of DMSO. Cell extracts diluted in homogenization buffer (48 l) were incubated with substrate for 45 min at 37°C. In some experiments, PLA2 activity was measured after addition of CaCl2 to the homogenization buffer to a final Ca 2ϩ concentration of 2 mM. The reaction was stopped by adding 50 l of ethanol containing cold AA and acetic acid. [ 14 C]AA was separated from other lipids by thin-layer chromatography as described above.
Immunoblotting. Immunoblotting was done as described previously (45) . Glomeruli were isolated from rat kidney cortices by differential sieving (purity of glomeruli was Ͼ95%) (22) . Briefly, cells or isolated glomeruli were lysed in buffer containing 10 mM sodium pyrophosphate, 25 mM NaF, 2 mM Na3VO4, 2% Triton X-100, 250 mM NaCl, 20 mM Tris, 2 mM EDTA, 2 mM EGTA, and a protease inhibitor cocktail (Roche Diagnostics), pH 7.4. After centrifugation at 14,000 g, soluble components were collected and the protein concentration was quantified using the Bio-Rad assay. Equal quantities of proteins were separated by SDS-PAGE under reducing conditions. Proteins were then transferred to a nitrocellulose membrane, and the membrane was blocked at room temperature for 60 min with 5% dry milk in TBS-T wash buffer containing 10 mM Tris, pH 7.5, 50 mM NaCl, 2.5 mM EDTA, and 0.05% Tween 20. The nitrocellulose membrane was subsequently incubated with primary antibody for 60 min at 22°C, washed three times in TBS-T wash buffer, and incubated with the appropriate secondary antibody conjugated to horseradish peroxidase for 60 min at 22°C. Immunoreactive proteins were then visualized using ECL.
RT-PCR. RNA samples were isolated from cells or normal rat glomeruli using TRIzol reagent (Invitrogen) according to the manufacturer's instructions (3). RT-PCR was performed with an Invitrogen Superscript II One-Step PCR Kit. Primers designed for iPLA 2␤ flanked the insertion site of exon 9 (forward: TTGGGGCAGAAG-TAGACACC, reverse: GTCAGCATCACCTTGGGTTT) to distinguish short and long isoforms. Primers for iPLA 2␥ were ATTGATGGTG-GAGGAACAAGA (forward) and ATGGCCTGCCACATTTTATAC (reverse). PCR for iPLA 2␤ and iPLA2␥ were performed with 35 cycles of 30 s at 94°C, 1 min at 55°C, and 1 min at 72°C. Experimental conditions for EP4 and ␤-actin PCR were described previously (3) . PCR products were separated by agarose gel electrophoresis and visualized after staining with ethidium bromide.
PGE 2 assay. At the end of incubations with complement, supernatants were collected for measurement of PGE2. The samples were further diluted 100-to 200-fold in assay buffer, and PGE2 was quantified using an enzyme immunoassay kit from Cayman Chemical, according to the manufacturer's instructions (45) .
Measurement of intracellular Ca 2ϩ concentration. The method has been described in detail (20) . Briefly, GEC were loaded in suspension with 5 M fura 2-AM in buffer containing 0.5 mM CaCl 2 for 30 min at 37°C. After washing, aliquots of cells were placed into a spectrofluorometer in Ca 2ϩ -free Krebs-Henseleit buffer containing 2 mM EGTA. Fluorescence of fura 2 was monitored continuously (emission wavelength of 510 nm, excitation wavelengths alternating between 340 and 380 nm) at 37°C. Release of Ca 2ϩ from intracellular storage sites was initiated by the addition of 5 M ionomycin.
Lactate dehydrogenase assay. GEC were incubated with antibody and complement as described above. At the end of the incubations, supernatants were collected and the remaining cell contents were solubilized with Triton-X 100 (1%). The supernatant and Triton fractions were assayed for lactate dehydrogenase (LDH) by incubating 100 l of the sample in 1.5 ml glycine (58 mM)/lactate buffer (0.2 M), containing NAD (4.8 mg/ml) at 37°C and monitoring absorbance at 340 nm in a spectrophotometer. Specific LDH release was calculated using the formula (NS Ϫ HIS)/(100 Ϫ HIS) ϫ 100 (40) .
Statistics. Data are presented as mean Ϯ SE. The t-statistic was used to determine significant differences between two groups. For more than two groups, one-way ANOVA was used to determine significant differences among groups. Where significant differences were found, individual comparisons were made between groups using the t-statistic, and adjusting the critical value according to the Bonferroni method (see Fig.s 5-8 ). Two-way ANOVA was used to determine significant differences in multiple measurements among groups (see Figs. 3B and 4B). . As a second step, GEC were incubated with or without purified C8 and C9 without Ca 2ϩ (i.e., in the presence of EGTA). The C8DS leads to assembly of the nascent C5b-7 complex, while addition of C8 and C9 allows assembly of the C5b-9 transmembrane channel (in the absence of Ca 2ϩ ). Formation of C5b-9 resulted in a significant release of [ 3 H]AA, suggesting activation of an iPLA 2 (Fig. 1A) . C5b-9 also increased [ 3 H]DAG (Fig. 1A) , which reflects activation of phospholipase C.
RESULTS

C5b-9 induces
It should be noted that the incubation of GEC with C8 and C9 in buffer containing EGTA not only results in chelation of 3 H]AA, were incubated with antibody and 10% C8-deficient serum (C8DS) in buffer containing 0.5 mM Ca 2ϩ for 40 min. Then, GEC were washed and then incubated with or without purified C8 (2.0 g/ml) and C9 (1.5 g/ml; to assemble C5b-9) in buffer containing 1 mM EGTA. (Fig. 1B, top) . In contrast, if GEC were preincubated with 2 mM EGTA for 20 min before the addition of ionomycin, the Ca 2ϩ spike was almost completely abolished (Fig. 1B, bottom) , indicating that intracellular Ca 2ϩ stores were depleted. In preliminary studies, we determined that a 40-min incubation after the addition of C8 and C9 to the GEC with assembled C5b-7 complexes was required to increase free [ 3 H]AA significantly. Thus the effect of C5b-9 on [ 3 H]AA occurred while Ca 2ϩ stores were largely depleted. Expression of iPLA 2 isoforms. Several isoforms of the group VI iPLA 2 enzyme have been described, including iPLA 2 ␤ long, iPLA 2 ␤ short, and iPLA 2 ␥. To confirm endogenous expression of iPLA 2 in cultured rat GEC, as well as in rat glomeruli, RT-PCR was performed using primers to regions flanking exon 9 of the iPLA 2 ␤ isoform, and the coding sequence of iPLA 2 ␥ (Fig. 2) . PCR products consistent with iPLA 2 ␤ short ( Fig. 2A) , as well as iPLA 2 ␥ (Fig. 2B) were identified in GEC and glomeruli, and identities were confirmed by purification of bands and DNA sequencing. It should be noted that iPLA 2 ␤ RT-PCR in GEC and glomeruli showed additional faint bands, with a band that appeared to correspond to the predicted PCR product for iPLA 2 ␤ long. However, we were not able to confirm the identity of this band by purification and DNA sequencing, so it is not possible to make a firm conclusion regarding expression of iPLA 2 ␤ long. iPLA 2 protein expression was studied by immunoblotting. GEC and glomeruli express iPLA 2 ␤, and on SDS-PAGE, migration of this protein was slightly retarded, compared with COS cells transfected with iPLA 2 ␤ short (Fig. 2C) . Nevertheless, the protein migrated faster than the iPLA 2 ␤ long isoform. iPLA 2 ␥ has four potential translational initiation sites, yielding proteins of 88, 77, 74, and 63 kDa, respectively (47) . GEC and glomeruli predominantly express the 88-kDa isoform of iPLA 2 ␥ (Fig. 2D) .
Overexpression of iPLA 2 enzymes. To strengthen the link between complement and iPLA 2 activation, we transfected GEC with iPLA 2 ␥ and iPLA 2 ␤ short cDNAs. Clones were screened for stable expression by immunoblotting. Several clones of GEC transfected with iPLA 2 ␥ (GEC-iPLA 2 ␥) expressed the 88-, 77-, and 74-kDa isoforms of the enzyme (Fig. 3A) . Clones that express iPLA 2 ␤ short (GEC-iPLA 2 ␤) were also produced, and a representative clone is presented (Fig. 4A) . It should be noted that the transfected enzyme migrates slightly faster than the endogenous isoform.
To ensure that the expressed iPLA 2 proteins were enzymatically active, we further tested the extracts of stable subclones for iPLA 2 (Fig. 3B) or iPLA 2 ␤ short (Fig. 4B) (Fig. 5A) . As expected, complement-mediated [
3 H]AA release in GEC-iPLA 2 ␥ was inhibited significantly by the Fig. 2 . Expression of iPLA2. Endogenous expression of calcium-independent PLA2 (iPLA2␤; A) and iPLA2␥ mRNAs (B) in GEC and rat glomeruli was assessed using RT-PCR. Glomeruli were isolated from adult rat kidneys by differential sieving. Control lanes (Ϫ) were devoid of reverse transcriptase. A: GEC express iPLA2␤ short mRNA and possibly some iPLA2␤ long. iPLA2␤ RT-PCR in Chinese hamster ovary cells (CHO), which express only the short isoform (577 bp), is shown for comparison. B: GEC express iPLA2␥ mRNA. Expression of iPLA2 mRNAs in glomeruli is similar to expression in GEC (A and B) . Expression of iPLA2␤ (C) and iPLA2␥ proteins (D) in GEC and glomeruli was assessed by immunoblotting. COS cells transfected with iPLA2␤ short and long isoforms (C) and COS cells transfected with iPLA2␥ (D) are shown for comparison. C: GEC express an immunoreactive iPLA2␤ protein, whose molecular mass appears in between the long and short isoforms expressed by COS cells. D: GEC express iPLA2␥. The lower molecular mass bands in glomeruli and GEC (C), and COS-iPLA2␥ (D) are probably nonspecific.
iPLA 2 ␥-directed inhibitor BEL (1) (Fig. 5A ). This result confirms that in these cells, a significant portion of complementdependent (18, 37) .
In previous studies, we demonstrated that in GEC, C5b-9 can induce [ 3 H]AA release by activating cPLA 2 (37) . BEL was shown to have an inhibitory concentration (IC 50 ) 250-fold greater for iPLA 2 over cPLA 2 (1); nevertheless, we wanted to rule out the possibility that BEL had inhibited cPLA 2 . To determine whether BEL could affect cPLA 2 activity, we monitored PLA 2 activity in COS cells that had been transiently transfected with cPLA 2 . In the presence of 1 mM EGTA (Ca 2ϩ -free buffer), PLA 2 activity in COS cell extracts was low ( (Fig. 5B) , and by chemical anoxia/reexposure to glucose (recovery), an in vitro model of ischemia-reperfusion injury (24) (Fig. 5C) In previous studies, we demonstrated that overexpression of cPLA 2 in GEC (ϳ5-to 10-fold above endogenous levels) amplified the C5b-9-dependent release of [ 3 H]AA (18, 37) . In contrast, the increases in free [ 3 H]AA induced by H 2 O 2 or anoxia/recovery (Fig. 5, B and C) were not amplified in GEC that overexpress cPLA 2 (Table 2) , suggesting lack of involvement of cPLA 2 . Furthermore, these increases in [ 3 H]AA were attenuated in the presence of BEL (Table 2) . Together, the results suggest that iPLA 2 ␥ (and possibly other iPLA 2 s), but not cPLA 2, is activated by H 2 O 2 and anoxia/recovery, whereas both iPLA 2 ␥ and cPLA 2 are activated by complement.
In some cells, AA may be derived from metabolism of DAG. Thus, in the above experiments, we also monitored changes in [ 3 H]DAG. Complement (Fig. 1) ]DAG production (data not shown), even though BEL is reported to inhibit phosphatidic acid phosphohydrolase, which mediates generation of DAG from phosphatidic acid. Based on these results, it is unlikely that inhibition of DAG production was the mechanism by which BEL attenuated AA release in GEC. Fig. 4 . Overexpression of iPLA2␤ in GEC. A: lysates of control GEC and a clone of GEC stably transfected with iPLA2␤ (GEC-iPLA2␤) were immunoblotted with an antibody to iPLA2␤. COS cells are shown for comparison. In GEC-iPLA2␤, the transfected enzyme migrates slightly more quickly than the endogenous, and it comigrates with iPLA2␤ short in transfected COS cells. B: serially increasing amounts of cell extracts from GEC-iPLA2␤ and GECNeo were incubated with [ 14 C]phosphatidylethanolamine (PE) for 45 min at 37°C in the absence of Ca 2ϩ . The data were analyzed using 2-way ANOVA. P Ͻ 0.05 iPLA2␤ vs. Neo, 6 measurements.
Fig. 3. Overexpression of iPLA2␥ in GEC.
A: lysates of control GEC and clones of GEC stably transfected with iPLA2␥ (GEC-iPLA2␥) were immunoblotted with an antibody to iPLA2␥. GEC-iPLA2␥ express 88-, 77-, and 74-kDa splice variants of the ␥-enzyme. Expression of endogenous iPLA2␥ in parental GEC is not visible at this exposure. B: serially increasing amounts of cell extracts from GEC-iPLA2␥ and GEC-Neo were incubated with [
14 C]PE for 45 min at 37°C in the absence of Ca 2ϩ . The data were analyzed using 2-way ANOVA. The increase in PLA2 activity was significant. P Ͻ 0.0001 iPLA2␥ vs. Neo, 6 measurements.
iPLA 2 -dependent AA release is coupled to production of PGE 2 . The above experiments demonstrated that complement can induce release of [ 3 H]AA via activation of iPLA 2 ␥. In the next set of experiments, we investigated whether free AA could be metabolized via COX to eicosanoids. We monitored production of PGE 2 , which was shown to be a major metabolite of COX in GEC (45) . GEC-Neo produced a small amount of PGE 2 in response to complement, which appeared to be inhibited by indomethacin but not by BEL (HIS: 16 Ϯ 9, HIS/BEL: 7 Ϯ 4, NS: 46 Ϯ 15, NS/BEL: 50 Ϯ 14, NS/Indo: 18 Ϯ 2 pg/ml) (Fig. 6) . However, when analyzed together with GEC-iPLA 2 ␥, these changes were not statistically significant.
Overexpression of iPLA 2 ␥ did not affect basal PGE 2 production significantly during short-term incubation (Fig. 6, 60 -min incubation), while there was a small increase in PGE 2 in culture media of GEC-iPLA 2 ␥, compared with GEC-Neo, after 2 days of cell culture (GEC-Neo: 284 Ϯ 47 pg/ml, GECiPLA 2 ␥: 519 Ϯ 8 pg/ml, P Ͻ 0.05, 3 experiments). However, after incubation with complement, PGE 2 production was ϳ20-fold greater in GEC-iPLA 2 ␥ relative to GEC-Neo (Fig. 6 ). The effect of complement was inhibited significantly by BEL and by the nonselective COX inhibitor indomethacin (Fig. 6 ). Thus complement-induced production of PGE 2 parallels the release of [ (Fig. 5A) . Overexpression of iPLA 2 ␥ limits complement-mediated GEC injury. We reported previously that overexpression of cPLA 2 in GEC increased the susceptibility to complement-mediated cytotoxicity (18) . We next tested whether overexpression of iPLA 2 ␥ has a similar effect. Complement-mediated cytotoxicity was monitored as the release of LDH. Antibody-sensitized GEC-Neo or GEC-iPLA 2 ␥ were incubated with normal serum at serially increasing concentrations (to assemble C5b-9) for 100 min. The protocol allows for complement to activate iPLA 2 , but with increasing incubation time and complement dose, a portion of the cells will undergo lysis. LDH release was attenuated significantly in GEC-iPLA 2 ␥, compared with GECNeo (Fig. 7A) . Further studies in GEC-iPLA 2 ␥ showed that the cytoprotective effect of iPLA 2 ␥ was reversed by the addition of BEL, and to a lesser extent by the addition of indomethacin (Fig. 8A) . Indomethacin did not reverse the cytoprotective 3 H]AA is enhanced in GEC that overexpress GEC-iPLA2␥. GEC-iPLA2␥, and GEC-Neo were labeled with [effect of iPLA 2 ␥ completely, despite complete inhibition of PGE 2 production (Fig. 6) . Therefore, part of the cytoprotective effect of iPLA 2 ␥ may have been independent of eicosanoid production. In keeping with previous results, GEC-Neo tended to be protected by the addition of indomethacin, since the activation of other PLA 2 s by complement was shown to involve mobilization of AA and downstream metabolism to bioactive eicosanoids with a cytotoxic effect (46). Fig. 6 . Complement-induced production of PGE2 is enhanced in GEC that overexpress GEC-iPLA2␥. Incubation with complement is described in Fig. 5 . In some experiments, BEL (25 M) or the COX inhibitor indomethacin (10 M) were included in the incubations. GEC-iPLA2␥ produced significantly more PGE2 than GEC-Neo in response to complement, and this increase was attenuated by the addition of BEL or indomethacin. *P Ͻ 0.0001 GEC-iPLA2␥ vs. GEC-Neo (NS), **P Ͻ 0.0001 NS/BEL vs. NS (GEC-iPLA2␥), ϩP Ͻ 0.0001 NS/indomethacin vs. NS (GEC-iPLA2␥), 5 experiments. Fig. 7 . Overexpression of iPLA2␥ (A), or iPLA2␤ (B) limits complementmediated GEC injury. GEC-iPLA2␥, GEC-iPLA2␤, and GEC-Neo were incubated with anti-GEC antiserum and then with 2.5, 5.0, or 7.5% NS for 100 min (HIS in control incubations). Cell injury was monitored as release of LDH. A: *P Ͻ 0.0001 GEC-iPLA2␥ vs. GEC-Neo (5.0% NS), **P Ͻ 0.025 GEC-iPLA2␥ vs. GEC-Neo (7.5% NS), 3 experiments. Similar results were obtained when these experiments were performed using another GEC-Neo clone. B: *P Ͻ 0.005 GEC-iPLA2␤ vs. GEC-Neo (2.5% NS), **P Ͻ 0.0001 GEC-iPLA2␤ vs. GEC-Neo (5.0% NS), ϩP Ͻ 0.0001 GEC-iPLA2␤ vs. GEC-Neo (7.5% NS), 4 experiments. Fig. 8 . Protective effect of iPLA2␥, but not iPLA2␤ on complement-mediated injury is prostaglandin dependent. A: GEC-iPLA2␥ and GEC-Neo were preincubated with or without BEL (25 M) or indomethacin (10 M) for 30 min. Cells were then incubated with anti-GEC antiserum and 5% NS (HIS in control) for 100 min. *P Ͻ 0.0001 GEC-iPLA2␥ vs. GEC-Neo (NS), **P Ͻ 0.0001 NS/BEL vs. NS (GEC-iPLA2␥), ϩP Ͻ 0.0001 NS/indomethacin vs. NS (GEC-iPLA2␥), 3 experiments. B: GEC-iPLA2␥ and GEC-Neo were preincubated with or without NS 398 (10 M) or SC560 (10 M) for 30 min. Cells were then incubated as described above. *P Ͻ 0.0001 GEC-iPLA2␥ vs. GEC-Neo (NS), **P Ͻ 0.04 NS/NS398 vs. NS (GEC-iPLA2␥), ϩP Ͻ 0.002 NS/SC560 vs. NS (GEC-iPLA2␥), 4 experiments. C: GEC-iPLA2␤ and GECNeo were treated as in A. *P Ͻ 0.01 GEC-iPLA2␤ vs. GEC-Neo (NS), 4 experiments.
To further elucidate which COX enzyme was responsible for the cytoprotective effect of iPLA 2 ␥, we included isoformspecific COX inhibitors NS 398 (COX-2) and SC560 (COX-1) in incubations with complement (Fig. 8B) . Both inhibitors partially reversed the cytoprotective effect of iPLA 2 ␥, suggesting that both COX isoforms were involved. Previously, we showed that C5b-9 upregulates the expression of COX-2 in GEC, although expression of COX-1 was not affected (45) . Interestingly, COX-2 was upregulated in resting GEC-iPLA 2 ␥, i.e., independently of a complement effect (Fig. 9A ). In contrast, expression of COX-1 was not significantly different between GEC-iPLA 2 ␥ and GEC-Neo (Fig. 9B) . These results provide further support for the view that following activation of iPLA 2 ␥, both COX enzymes are involved in metabolism of AA.
In GEC, the principal receptor for PGE 2 is EP 4 (3) , and earlier studies have demonstrated that signaling via EP 4 is cytoprotective (3). Overexpression of iPLA 2 ␥ in GEC did not, however, affect expression of EP 4 receptor mRNA (Fig. 10) . Thus the cytoprotective effect of iPLA 2 ␥ and eicosanoids most likely occurs independently of changes in EP 4 receptor expression.
Role of iPLA 2 ␤ in complement-dependent GEC injury. By analogy to the studies that addressed iPLA 2 ␥ (described above), we employed GEC-iPLA 2 ␤ to study complementmediated effects on [ 3 H]AA release and cell injury. In contrast to GEC-iPLA 2 ␥, there was no amplification of complementmediated [ 3 H]AA release in GEC-iPLA 2 ␤. Levels of free [ 3 H]AA in GEC-Neo and GEC-iPLA 2 ␤ after exposure to HIS were 1.5 Ϯ 0.2 and 2.5 Ϯ 0.3% of total radioactivity, respectively, while after exposure to NS, [ 3 H]AA increased to 4.1 Ϯ 0.7 (P Ͻ 0.0001) and 3.3 Ϯ 0.2% of total radioactivity, respectively (the increase in GEC-iPLA 2 ␤ was not statistically significant; 3 experiments). After incubation of antibody-sensitized GEC with serially increasing concentrations of complement, LDH release was attenuated significantly in GECiPLA 2 ␤, compared with GEC-Neo (Fig. 7B) . However, in contrast to GEC-iPLA 2 ␥, neither BEL nor indomethacin reversed the protective effect of iPLA 2 ␤ (Fig. 8C) . Thus, while overexpression of iPLA 2 ␤ in GEC was not involved in complement-induced [ 3 H]AA release, it was nonetheless cytoprotective.
DISCUSSION
The present study demonstrates that in GEC, assembly of C5b-9 resulted in a significant release of [ 3 H]AA in Ca 2ϩ -free medium, suggesting activation of an iPLA 2 ( Fig. 1) . GEC endogenously express iPLA 2 ␤ short, although on SDS-PAGE, the protein appeared to be slightly greater in molecular mass, compared with transfected iPLA 2 ␤ short in COS cells (Fig. 2) . Perhaps the endogenous iPLA 2 ␤ short undergoes a posttranslational modification in GEC, which accounts for the slight increase in size. GEC also express the 88-kDa isoform of iPLA 2 ␥ (Fig. 2) . Both iPLA 2 ␤ short and iPLA 2 ␥ were also expressed in isolated normal glomeruli (Fig. 2) . Overexpression of iPLA 2 ␥ in GEC augmented complement-dependent [ 3 H]AA release, compared with GEC-Neo, and furthermore the [ 3 H]AA release in GEC-iPLA 2 ␥ was attenuated by BEL (Fig.  5) . These results indicate that activation of complement is coupled with the activation of iPLA 2 ␥. It should also be noted that the AA mobilized by iPLA 2 ␥ was accessible to COX and could be metabolized to prostanoids (Fig. 6 ). An earlier study also showed coupling of iPLA 2 ␥ with COX-1 in HEK293 cells (35) . In contrast to iPLA 2 ␥, overexpression of iPLA 2 ␤ in GEC did not amplify complement-dependent [ 3 H]AA release. By analogy to iPLA 2 ␥, overexpression of cPLA 2 in GEC was previously shown to augment complement-dependent [ 3 H]AA release and prostanoid production, compared with GEC-Neo. However, overexpression of group IIA sPLA 2 in GEC was similar to iPLA 2 ␤, i.e., neither enzyme amplified complement-dependent [ 3 H]AA release (37) . Previous studies also demonstrated that complement induces serine 505 phosphorylation of cPLA 2 in GEC, in association with an increase in enzymatic activity (18) and that glomerular cPLA 2 is phosphorylated in PHN (21) . This posttranslational modification of cPLA 2 , which is generally associated with activation, has been described with multiple agonists (27) . iPLA 2 ␥ activity has been reported to increase after stimulation with PMA or ATP, but the mechanism is unknown at present and will require further study (16, 28) . An alternate mechanism of iPLA 2 ␥ activation may involve modification of phospholipids (e.g., by C5b-9-induced deformability of the membrane lipid bilayer, or by lipid peroxidation) (9, 36) , such that there is increased substrate availability to iPLA 2 ␥. The overexpression models of the various PLA 2 s are invaluable in defining links of C5b-9 assembly with PLA 2 isoform activation. We have expressed (Fig. 5) , providing further support for the view that iPLA 2 ␥ activity can be enhanced by specific stimuli, including ischemia-reperfusion. In contrast to complement, the increases in free [ 3 H]AA induced by H 2 O 2 or anoxia/recovery (Fig. 5 , B and C) were not amplified in GEC that overexpress cPLA 2 ( Table 2 ). Other studies have demonstrated that release of AA in response to H 2 O 2 was mediated by cPLA 2 in renal tubular epithelial and mesangial cells (26, 41) . Thus H 2 O 2 -coupled AA mobilization may be cell specific (10) .
Various PLA 2 enzymes have been shown to regulate pathways of cell injury in several experimental disease models (5, 11, 12, 15, 39) . In vivo, assembly of C5b-9 in GEC is associated with sublethal GEC injury and proteinuria; however, it is not practical to assay proteinuria in cell culture models. Instead, in cultured GEC, we have assayed C5b-9-mediated injury as cytolysis (LDH release), and it has been shown that cytolysis in culture correlates with proteinuria in vivo, in the context of injury associated with generation of prostanoids (46) , p38 activation (3), and ER stress (22) . The present study demonstrates that overexpression of iPLA 2 ␥ attenuated complement-induced GEC injury, and the effect was reversed by BEL (Fig. 8) . In addition, the attenuation of complement-induced GEC injury was partially reversed in the presence of a nonselective COX inhibitor, as well as with selective inhibitors of the COX-1 and -2 isozymes (Fig. 8) . Thus cytoprotection was, at least in part, mediated via generation of prostanoids, most likely through both COX-1 and COX-2. In support of this view are our earlier results, which show that GEC express COX-1 constitutively and that C5b-9 induces COX-2 expression (45). Interestingly, while GECiPLA 2 ␥ also express COX-1 constitutively, expression of COX-2 was markedly upregulated in these cells under basal conditions (Fig. 9) . The mechanism by which iPLA 2 ␥ may be enhancing basal COX-2 expression will require elucidation, but it is noteworthy that similar COX-2 upregulation was observed in HEK293 cells overexpressing iPLA 2 ␥ and stimulated with interleukin-1␤/fetal calf serum (35) . However, despite the increase in basal COX-2 expression in GEC-iPLA 2 ␥, basal PGE 2 production was modestly increased in these cells only after long term culture (Fig. 6) , indicating that the AA substrate was rate limiting. COX inhibitors did not enhance complement-induced injury in GEC-Neo and actually tended to reduce cytotoxicity (Fig. 8) . This result is in keeping with earlier studies in GEC-Neo, which showed that COX inhibitors protected the cells from complement-induced cell death. Finally, it should be noted that inhibition of COX in PHN in vivo with nonselective or with COX-2-selective inhibitors reduced proteinuria (45, 46) .
There would seem to be an apparent contradiction in that production of prostanoids was cytoprotective in GEC-iPLA 2 ␥ but exacerbated cytotoxicity in other GEC lines (46) . Possibly, individual prostanoids downstream of COX (and/or intracellular localization of their production) are responsible for inducing a cytoprotective vs. cytotoxic effect. For example, in earlier studies in GEC-Neo, where COX inhibition protected the cells from complement-induced injury, the protective effect of the COX inhibitor could be reversed by the addition of a thromboxane A 2 analog, but not PGE 2 (46) . Among the PGE 2 receptors, GEC predominantly express EP 4 as well as some EP 1 receptors (3). Previously, it was demonstrated that exogenous PGE 2 was protective against apoptosis induced by serum deprivation and that these effects were reversed by an EP 4 receptor antagonist. Moreover, exogenous PGE 2 could also attenuate puromycin aminonucleoside-induced GEC injury, indicating that PGE 2 is cytoprotective (3). In the present study, we have shown that GEC-iPLA 2 ␥ express EP 4 receptor mRNA, at levels similar to GEC-Neo (Fig. 10) . Thus a PGE 2 -EP 4 receptor pathway could mediate the cytoprotective effect of iPLA 2 ␥ in complementdependent injury. Further studies will be required to confirm this hypothesis more directly.
In GEC-iPLA 2 ␥, BEL reversed the cytoprotective effect of iPLA 2 to a greater extent than indomethacin (Fig. 8) , suggesting that mechanisms distinct from AA metabolism, but nonetheless related to iPLA 2 catalytic activity, also contributed to the cytoprotective effects of iPLA 2 . One possible mechanism is that the iPLA 2 enzyme facilitates activation of the ER stress response, a cytoprotective response shown to be activated in GEC exposed to complement C5b-9 (22) . At least some iPLA 2 ␥ isoforms may be localized at the membrane of the ER (17); consequently, iPLA 2 ␥ could perturb the ER membrane sufficiently to initiate the ER stress response, which may limit complement-induced injury. Additional studies will be required to determine the subcellular localization of iPLA 2 ␥ in GEC, in particular, whether iPLA 2 ␥ is found at the ER. Of interest, iPLA 2 ␥ protected mitochondria in renal proximal tubular cells from oxidant-induced lipid peroxidation and dysfunction (28) , and iPLA 2 ␥ knockout mice show defects in mitochondrial functions and mitochondrial lipid composition (32) . Thus mitochondria are another potential target of iPLA 2 ␥ in GEC.
The present study demonstrates that overexpression of iPLA 2 ␤ in GEC also attenuated complement-induced GEC injury (Fig. 7) , and this effect occurred in the absence of stimulated [ 3 H]AA release and was not blocked by acute incubation with BEL and indomethacin (Fig. 8). Another study failed to demonstrate stimulus-coupled AA release with iPLA 2 ␤, but there are also reports of protein kinase C and calmodulin involvement in iPLA 2 ␤ activation (2, 5) . In the absence of complement-induced [ 3 H]AA release or acute inhibition, our results suggest that overexpression of iPLA 2 ␤ may have induced "preconditioning" of GEC, such that the cells were able to resist complement-mediated injury. There were no significant differences in basal free [ 3 H]AA levels between GEC-Neo and GEC-iPLA 2 ␤, but it is possible that there was enhanced turnover of [ 3 H]AA in the latter. This view is consistent with earlier studies, which have determined that iPLA 2 ␤ may be involved in both deacylation of membrane phospholipids and production of lysophospholipid acceptors (4, 6, 8) . The mechanisms of phospholipid metabolism and cytoprotection in GEC-iPLA 2 ␤ will require further study.
While the role of complement in the PHN model of membranous nephropathy is appreciated, the ensuing biological changes in GEC are complex and include both proinjurious and protective stimuli (19) . The role of PLA 2 s in complementmediated GEC injury has been addressed in a number of studies (19) . The present study suggests that in addition to cPLA 2 , iPLA 2 may be involved in the pathogenesis of PHN, as complement-mediated GEC injury was reduced in the context of iPLA 2 overexpression. Based on previous studies, there are cytoprotective and injurious aspects related to the complementmediated activation of cPLA 2 and production of prostanoids, in both cell culture and in vivo models. Further studies will be required to delineate these effects more precisely and define the interplay between the various PLA 2 isoforms. Current treatment approaches to idiopathic membranous nephropathy are nonspecific and not very effective. Modulation of specific PLA 2 family enzymes may represent a mechanism of limiting GEC injury and maintaining the integrity of the permselective barrier.
